|
|
SonoMedix,
Inc.
SonoMedix, Inc. is developing
a novel nano-acoustic sensor based on technology licensed from Drexel
University. The first product targets the home and physician office
market for anti-coagulation monitoring (Coumadin) with a total CMS
reimbursed value of over $1.2B. The total market is less than 5%
penetrated despite the compelling clinical benefit. Located in the
University Science Center in Philadelphia, the company is leveraging
existing academic expertise. The product development program is
being supported by a well credentialed team of engineers and consultants
with extensive experience in the ultrasound space. |
